Mainz Biomed N.V [NASDAQ: MYNZ] plunged by -$0.05 during the normal trading session on Wednesday and reaching a high of $1.66 during the day while it closed the day at $1.6.
Mainz Biomed N.V stock has also gained 2.56% of its value over the past 7 days. However, MYNZ stock has declined by -20.00% in the 3 months of the year. Over the past six months meanwhile, it has lost -47.71% and lost -83.46% year-on date.
The market cap for MYNZ stock reached $8.66 million, with 0.53 million shares outstanding. Compared to the average trading volume of 137.69K shares, MYNZ reached a trading volume of 6692499 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Mainz Biomed N.V [MYNZ]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MYNZ shares is $14.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MYNZ stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Mainz Biomed N.V shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 14, 2025. The new note on the price target was released on November 25, 2024, representing the official price target for Mainz Biomed N.V stock.
The Price to Book ratio for the last quarter was 5.00, with the Price to Cash per share for the same quarter was set at 0.35.
MYNZ stock trade performance evaluation
Mainz Biomed N.V [MYNZ] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.56. With this latest performance, MYNZ shares dropped by -3.61% in over the last four-week period, additionally sinking by -47.71% over the last 6 months – not to mention a drop of -62.96% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MYNZ stock in for the last two-week period is set at 48.29, with the RSI for the last a single of trading hit 0.1490, and the three-weeks RSI is set at 0.1345 for Mainz Biomed N.V [MYNZ]. The present Moving Average for the last 50 days of trading for this stock 1.6249, while it was recorded at 1.6480 for the last single week of trading, and 3.1174 for the last 200 days.
Mainz Biomed N.V (MYNZ) Capital Structure & Debt Analysis
Mainz Biomed N.V (MYNZ) Efficiency & Liquidity Metrics
Based on Mainz Biomed N.V’s (MYNZ) latest financial statements, the Debt-to-Equity Ratio is 1.23%, indicating its reliance on debt financing relative to shareholder equity.
Mainz Biomed N.V (MYNZ) Efficiency & Liquidity Metrics
Mainz Biomed N.V [MYNZ]: Institutional Ownership
There are presently around $7.13%, or 7.23%% of MYNZ stock, in the hands of institutional investors. The top three institutional holders of MYNZ stocks are: NORTHERN TRUST CORP with ownership of 29934.0 shares, which is approximately 0.1414%. VONTOBEL HOLDING LTD., holding 25000.0 shares of the stock with an approximate value of $$10025.0 in MYNZ stocks shares; and VONTOBEL HOLDING LTD., currently with $$6090.0 in MYNZ stock with ownership which is approximately 0.0718%.
